Checking measles vaccine response in children with sickle cell disease

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study will enroll children aged 6 months to 6 years with confirmed sickle cell disease who are due for a measles vaccine. Two cohorts will be followed: one receiving the first measles vaccine (MV1) and one receiving the second (MV2). Blood samples will be collected before vaccination and at 4 and 8 weeks after vaccination to measure antibody responses. Sites include Cincinnati Children’s Hospital Medical Center and collaborating hospitals in Ghana and Tanzania.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Participants with confirmed Sickle Cell Disease.
2. Participants 6 months and 6 years of age and due for measles vaccination within 3 months per national guidelines.
3. Willing and able to provide informed consent
4. Ability to comply with study related evaluations and follow-up visits.

Exclusion Criteria:

1\. Known primary immunodeficiency syndrome, cancer, or acquired immunodeficiency syndrome (AIDS) that would preclude vaccination with live virus vaccines.

Where it's running

• Cincinnati Children's Hospital Medical Center
  Cincinnati, Ohio, United States Recruiting
• Korle Bu Teaching Hospital
  Accra, Ghana, Ghana Recruiting
• Bugando Medical Centre
  Mwanza, Tanzania Recruiting

Study contacts

• Principal investigator: Alexandra Power-Hays, MD — Children's Hospital Medical Center, Cincinnati
• Study coordinator: Teresa Latham
• Email: Teresa.Latham@cchmc.org
• Phone: 513-803-7922

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Senicapoc for Sickle Cell Disease with Hemolytic Phenotype

  A mid-stage study tests whether daily senicapoc helps people with sickle cell disease who have ongoing red blood cell breakdown and low hemoglobin, despite hydroxyurea, by comparing it to a placebo over 24 weeks.

  Recruiting at 4 sites Phase 2 Biossil Inc. · Toronto, Ontario and 3 other locations · NCT07282210

• Using alendronate to treat osteonecrosis in adults with sickle cell disease

  This study is testing if a weekly medication called alendronate can help adults with sickle cell disease who have bone pain from osteonecrosis feel better and improve their bone health.

  Recruiting Phase 2 University of California, Davis · Sacramento, California · NCT06016634

• Evaluating a single dose of CTX001 for treating transfusion-dependent beta-thalassemia and severe sickle cell disease

  This study is testing a single dose of a new treatment called CTX001 to see if it can help people with transfusion-dependent beta-thalassemia or severe sickle cell disease feel better.

  Recruiting at 6 sites Phase 3 Vertex Pharmaceuticals Incorporated · New York, New York and 5 other locations · NCT05477563

• Haploidentical stem cell transplantation for sickle cell disease

  This study is testing a new type of stem cell transplant for people with sickle cell disease to see if it can cure the disease while causing fewer complications.

  Recruiting at 4 sites Phase 2 University of Regensburg · Vienna and 8 other locations · NCT04201210

• Understanding hydroxyurea effects during pregnancy and breastfeeding in women with sickle cell disease

  This study looks at how taking hydroxyurea during pregnancy and breastfeeding affects women with sickle cell disease and their babies to better understand the risks and outcomes.

  Recruiting Children's Hospital Medical Center, Cincinnati · Cincinnati, Ohio · NCT04093986

• Collecting blood samples to study sickle cell disease

  This study is collecting blood samples from healthy people and those with sickle cell disease to see if new drugs can help stop red blood cells from sickling.

  Recruiting National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT00542230

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.